RecruitingNot ApplicableNCT05939362

New Imaging Biomarkers Predictive of MA Progression

Identifying Imaging Biomarkers Predictive of Disability Progression in Alzheimer's Disease: Pilot Study


Sponsor

Poitiers University Hospital

Enrollment

80 participants

Start Date

Oct 2, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death. Ultra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.


Eligibility

Min Age: 60 YearsMax Age: 90 Years

Inclusion Criteria6

  • French-speaking patients aged 60 to 90 years,
  • Patient in the context of Alzheimer's disease \* for which imaging after MRI is prescribed as part of the usual diagnostic process,
  • \*Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR/RI defined by a sum of LR \< 17/48 and sum of RT \< 40/48 +/- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +/- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery).
  • MMSE score ≥18,
  • Written informed consent after the patient has been informed,
  • Progressive decline for at least 6 months.

Exclusion Criteria5

  • Partially or completely illiterate patient unable to read and write,
  • Patient with an absolute contraindication to 7T MRI
  • Severe psychiatric pathology not balanced,
  • Non-degenerative neurological disease (stroke, multiple sclerosis ...),
  • Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score \> 3)

Interventions

OTHERMRI follow-up

MRI follow-up for patient with early onset Alzheimer's disease


Locations(1)

Chu Poitiers

Poitiers, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05939362


Related Trials